The treatment, called relugolix–estradiol–norethisterone - also known as relugolix combination therapy or Ryeqo, works by blocking specific hormones that contribute to endometriosis, while also providing necessary hormone replacement in a single daily tablet.

Around 1,000 women per year with endometriosis could benefit from this new treatment that:

• Starts working more quickly than injectable alternatives
• Can be taken at home rather than at clinics
• Combines all needed hormones in one pill
• Returns hormone levels to normal faster when stopped.

Helen Knight, our director of medicines evaluation, said: ‘This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer.'

She added: ‘Instead of travelling to clinics for injections, there is now a daily tablet that can be taken at home. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects.'

The treatment will be available through routine NHS commissioning for patients for whom medical or surgical treatment for endometriosis has failed.